On April 24, Matwings Technology launched MatwingsVenus™, a conversational protein R&D agent. MatwingsVenus™ enables the retrieval of tens of billions of annotated protein data. It integrates over 200 protein design tools, assembles more than 50 platform-certified experts, and provides 30+ Skills optimized by cross-field specialists.

Through simple natural language interaction, users can leverage the agent to accomplish a full range of protein R&D tasks, including industry research, protein database search, protein design (e.g., enzyme mining, directed evolution, and de novo design), automated wet-lab experiment, and online expert consultation.

To date, the MatwingsVenus™ Agent has empowered multiple successful application cases in innovative drug development and synthetic biology.

In the de novo design of immune regulatory receptor targets, the platform addressed core bottlenecks: insufficient reference of homologous drug molecules, scarce druggable binding hotspots, and ultra-high nM-level affinity of endogenous ligands. Leveraging AI Agent capabilities, we obtained dozens of novel binder molecules with potent in vitro cellular blocking activity.

In the engineering of the modification of the sweet protein Monellin, MatwingsVenus™ Agent delivered a library of 24 representative candidates and multiple high-quality variant strains. Several candidates exhibit over tenfold higher sweetness than wild-type proteins, while maintaining high thermostability at approximately 75°C.